Ananda Scientific and the University of Nebraska Medical Center will conduct a phase 2 clinical trial to assess safety and efficacy of Nantheia ATL5 in the treatment of PTSD in adults, according to a press release from Ananda.
It is expected that 240 participants will be enrolled in the upcoming double-blind, placebo-controlled, randomized trial involving the oral, cannabidiol-based treatment.
The study is being led by principal investigator Mathew Rizzo, MD, chair of the University of Nebraska Medical Center (UNMC) department of neurological sciences and chief physician for neurological